Related references
Note: Only part of the references are listed.Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
Nanshan Chen et al.
LANCET (2020)
Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia
Qun Li et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-The BRACE CORONA Trial
Renato D. Lopes et al.
AMERICAN HEART JOURNAL (2020)
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
Alexandra C. Walls et al.
CELL (2020)
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann et al.
CELL (2020)
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study
Xiaobo Yang et al.
Lancet Respiratory Medicine (2020)
Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis
Jing Yang et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study
Francisco J. de Abajo et al.
LANCET (2020)
Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China
Juyi Li et al.
JAMA CARDIOLOGY (2020)
Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19
Giuseppe Mancia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19
Harmony R. Reynolds et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19
Muthiah Vaduganathan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study
Chao Gao et al.
EUROPEAN HEART JOURNAL (2020)
Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis
Maria Elena Flacco et al.
HEART (2020)
Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality
Emil L. Fosbol et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study
Chao Gao et al.
EUROPEAN HEART JOURNAL (2020)
The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice
Xingxu Wang et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2016)
Impact of statin therapy at discharge on 1-year mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty
Giuseppe De Luca et al.
ATHEROSCLEROSIS (2006)
Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme
Jun Agata et al.
HYPERTENSION RESEARCH (2006)
Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction:: a systematic overview of data from individual patients
MD Flather et al.
LANCET (2000)
Share Paper
